Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Angeles Wealth Management LLC

Angeles Wealth Management LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,919 shares of the company’s stock after buying an additional 225 shares during the quarter. Angeles Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,197,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. CRA Financial Services LLC increased its holdings in shares of Novo Nordisk A/S by 4.4% in the 3rd quarter. CRA Financial Services LLC now owns 2,742 shares of the company’s stock worth $326,000 after acquiring an additional 116 shares during the period. Brown Miller Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 2.9% in the third quarter. Brown Miller Wealth Management LLC now owns 4,308 shares of the company’s stock valued at $512,000 after purchasing an additional 122 shares during the period. InTrack Investment Management Inc increased its stake in shares of Novo Nordisk A/S by 17.6% in the third quarter. InTrack Investment Management Inc now owns 4,608 shares of the company’s stock valued at $549,000 after purchasing an additional 689 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of Novo Nordisk A/S by 40.3% during the third quarter. Exchange Traded Concepts LLC now owns 63,962 shares of the company’s stock worth $7,616,000 after buying an additional 18,370 shares during the period. Finally, Renaissance Investment Group LLC grew its holdings in Novo Nordisk A/S by 2.3% in the 3rd quarter. Renaissance Investment Group LLC now owns 41,573 shares of the company’s stock worth $4,950,000 after buying an additional 932 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on NVO. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 0.9 %

Novo Nordisk A/S stock opened at $86.39 on Monday. The firm has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm’s 50 day moving average price is $91.46 and its two-hundred day moving average price is $111.36. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.